CCL2 and malignant glioma: TAMs act as therapeutic targets in malignant glioma via the C-C motif chemokine receptor 2/C-C motif chemokine ligand 2 (CCL2) pathway inhibition 11, phenotype transition, and colony stimulating factor 1 receptor blockade 12.